LinkedIn
Facebook
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 218 Press Releases
–
19 March 2025
19 March 2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s
–
12 March 2025
12 March 2025
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership…
–
06 March 2025
06 March 2025
Ipsen – February 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
21 February 2025
21 February 2025
Ipsen S.A. publishes its 2024 consolidated financial statements
Ipsen S.A. – 2024 Consolidated Financial Statements
–
13 February 2025
13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
Your dedicated contacts
-
Amy Wolf
Vice-Présidente, Stratégie de la marque Corporate et Communication
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links